Why the study?
Does the standardized VISITAG SURPOINT ablation workflow provide clinical safety and effectiveness in patients with paroxysmal atrial fibrillation?
Does the standardized VISITAG SURPOINT ablation workflow provide clinical safety and effectiveness in patients with paroxysmal atrial fibrillation?
The VISITAG SURPOINT module for paroxysmal AF ablation demonstrates >80% 12-month freedom from recurrence and an 83.1% first-pass isolation rate.
No takes yet. Share an insight, caveat, or question.
Supports VISITAG SURPOINT reproducibility in paroxysmal AF ablation; leaves open need for randomized confirmation before practice change.
Biase et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: